Open hrishikesh1985 opened 2 years ago
I would suggest changing the independent variable DOSE
to time
in your dataset and in your model. Perhaps in the future you can declare a different idependent variable in nlmixr
but right now it isn't possible.
There is some discussion on a similar issue in #517
I am not able to run below code using nlmixr2 package.
Data <- function() { ini({ temax <- -9.91 ted50 <- 11.9 eta.emax ~ pdDiag(2.9) add.err <-12.7 })
model({
emax <- (temax + eta.emax)
ed50 <- (ted50)
eff = (((emax)* time)/((ed50)+time))
eff ~ add(add.err)
})
}
Data_fit <- nlmixr(Data, data_import,est = "focei", foceiControl(derivMethod = "central" ))
Error: lotri syntax errors above
As per the USFDA guidance of Orlistate,( [https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020766.pdf] Data from PD study on fecal fat excretion should be analyzed based on dose-scale analysis to estimate relative bioavailability.
Model is y= E0 + Emax Dose Fi/ED50 + (Dose*Fi) Where y = Response, Dose = Administered dose, E0 = Baseline response in the absence of the drug, Emax = Fitted maximum drug effect, ED50 = Dose required to produce 50% the fitted maximum effect, and i = Treatment indicator (0 = Ref, 1 = Test), with the understanding that F0 = 1 and that F1 is the relative potency used to evaluate bioequivalence.
The same approach has to be used for albuterol Bronchoprovocation study. [https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020503.pdf] I am struggling to prepare the dataset and model (snapshot attached) in which have four treatment i,e, placebo, test, reference(2 doses) and from which F- relative bioavailability needs to be calculated
img.docx